Engagement of Pharmacists and Adoption of SGLT2 Inhibitors Among Diabetic Patients With CKD

Overview

This study evaluates the impact of pharmacists' proactive outreach on the initiation of SGLT2 inhibitors in diabetic patients with chronic kidney disease (CKD). The findings suggest that pharmacist engagement may significantly enhance the adoption of these medications, which are crucial for managing CKD and diabetes.

Background

Chronic kidney disease (CKD) affects nearly 15% of adults in the US and significantly contributes to morbidity and healthcare costs. SGLT2 inhibitors have emerged as a vital treatment option, demonstrating benefits in slowing CKD progression and improving cardiovascular outcomes. Despite their proven efficacy, the initiation rates of SGLT2 inhibitors remain low, highlighting the need for innovative strategies to enhance their use.

Data Highlights

No numerical data was provided in the source material.

Key Findings

• Pharmacists can play a critical role in identifying eligible patients for SGLT2 inhibitors.
• Proactive outreach by pharmacists is associated with increased initiation of SGLT2 inhibitors among patients with CKD and type 2 diabetes.
• Current guidelines recommend SGLT2 inhibitors for patients with CKD and an eGFR of 20 mL/min/1.73 m2 or greater.
• Engagement of clinical pharmacists may address low prescribing patterns of SGLT2 inhibitors.
• The study utilized a multicenter learning health system initiative across 8 Veterans Affairs health systems.

Clinical Implications

Healthcare providers should consider integrating pharmacists into the care team to optimize medication management for patients with CKD and diabetes. This collaborative approach may enhance the initiation and adherence to SGLT2 inhibitors, ultimately improving patient outcomes.

Conclusion

The involvement of pharmacists in patient care can significantly increase the initiation of SGLT2 inhibitors, addressing a critical gap in the management of CKD and diabetes. Further studies are warranted to explore the long-term impact of this strategy.

Related Resources & Content

1. European Journal of Preventive Cardiology, 2023 -- Insights on the Role of Glucagon-Like Peptide-1 Receptor Agonists in Managing Diabetes and Chronic Kidney Disease: Opportunities and Challenges
2. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Addressing Inequities in the Utilization of SGLT2 Inhibitors for Cardiorenal Benefits in Individuals With and Without Type 2 Diabetes
3. Frontiers in Endocrinology, 2026 -- Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study
4. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis | JAMA, 2026
5. conexiant — SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis
6. ADA Standards of Care 2026
7. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis | Acid Base, Electrolytes, Fluids | JAMA | JAMA Network
8. https://bmcprimcare.biomedcentral.com/counter/pdf/10.1186/s12875-025-02709-0.pdf